Datopotamab deruxtecan — complimentary MARA Rating report cover: pricing & reimbursement risk assessment for metastatic breast cancer.
Datopotamab deruxtecan has been assessed using the MARA Rating framework for its role in treating HR-positive, HER2-negative metastatic breast cancer. The overall MARA Score is A (Strong), with a numeric value of 3.08 out of 4. This score exceeds both the 5-year therapeutic-area average for oncology (3.0) and the industry-wide 5-year average (3.0), highlighting comparatively stronger market-access prospects.
Clinical Effectiveness: Very Strong Outcomes
Datopotamab deruxtecan showed very strong outcomes in the pivotal Phase 3 TROPION-Breast01 trial. Compared to standard chemotherapy, it delivered statistically significant improvements in progression-free survival (PFS) and higher response rates. Median PFS reached 6.9 months versus 4.9 months for chemotherapy, a benefit that was consistent across all examined subgroups, reinforcing the robustness of its efficacy profile.
Comparator Selection: Highest Rating
The study used eribulin, capecitabine, vinorelbine, and gemcitabine as comparators, all of which are standard-of-care chemotherapy regimens for this patient population. This ensured real-world relevance and strengthened the credibility of the findings.
Care-Pathway Integration: Top-Level Score
The treatment can be incorporated into existing practice without the need for new diagnostic tools or major workflow changes. Eligibility criteria were aligned with standard clinical assessments, simplifying the process for providers to identify suitable candidates.
About MARA Rating®
The MARA Rating synthesizes ten dimensions of market access risk: clinical efficacy, health-economic value, safety profile, comparator robustness, budget impact, and more. Each scored on a seven-level scale (A++ to C). We apply evidence-based weightings to generate a single risk score. A high MARA Score (A to A++) signals strong access prospects. A low score (B++ to C) denotes elevated pricing and reimbursement hurdles.
Unlock Premium Insights
Explore seven additional domains: Quality of Life (HRQoL), Cost-Effectiveness, Safety, Patient Population, Resource Use & Cost Implications, Evidence Quality, and Uncertainty. Available exclusively in Premium Insights at mararating.com.
Full Premium Report available upon request: Visit mararating.com or email at sales@mararating.com to learn more and unlock your access.
Disclaimer: The MARA Rating® is an independent opinion of a drug’s market-access risk profile and is provided for informational purposes only. Not as investment, medical, legal or any other type of advice. See our full disclaimer in mararating.com
Access this report and hundreds of others here: https://mararating.com/mara-ratings-list.